Your browser doesn't support javascript.
Casirivimab-Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19.
Razonable, Raymund R; Pawlowski, Colin; O'Horo, John C; Arndt, Lori L; Arndt, Richard; Bierle, Dennis M; Borgen, Molly Destro; Hanson, Sara N; Hedin, Michelle C; Lenehan, Patrick; Puranik, Arjun; Seville, Maria T; Speicher, Leigh L; Tulledge-Scheitel, Sidna M; Venkatakrishnan, A J; Wilker, Caroline G; Badley, Andrew D; Ganesh, Ravindra.
  • Razonable RR; Mayo Clinic, Rochester, MN, United States.
  • Pawlowski C; nFerence, Cambridge, MA, United States.
  • O'Horo JC; Mayo Clinic, Rochester, MN, United States.
  • Arndt LL; Mayo Clinic Health System, Eau Claire, WI, United States.
  • Arndt R; Mayo Clinic Health System, Eau Claire, WI, United States.
  • Bierle DM; Mayo Clinic, Rochester, MN, United States.
  • Borgen MD; Mayo Clinic, Rochester, MN, United States.
  • Hanson SN; Mayo Clinic Health System, Mankato, MN, United States.
  • Hedin MC; Mayo Clinic, Rochester, MN, United States.
  • Lenehan P; nFerence, Cambridge, MA, United States.
  • Puranik A; nFerence, Cambridge, MA, United States.
  • Seville MT; Mayo Clinic in Arizona, Phoenix, United States.
  • Speicher LL; Mayo Clinic in Florida, Jacksonville, United States.
  • Tulledge-Scheitel SM; Mayo Clinic, Rochester, MN, United States.
  • Venkatakrishnan AJ; nFerence, Cambridge, MA, United States.
  • Wilker CG; Mayo Clinic Health System Franciscan Healthcare, La Crosse, WI, United States.
  • Badley AD; Mayo Clinic, Rochester, MN, United States.
  • Ganesh R; Mayo Clinic, Rochester, MN, United States.
EClinicalMedicine ; 40: 101102, 2021 Oct.
Article in English | MEDLINE | ID: covidwho-1377701
ABSTRACT

BACKGROUND:

Real-world clinical data to support the use of casirivimab-imdevimab for the treatment of outpatients with mild to moderate coronavirus disease-19 (COVID-19) is needed. This study aimed to assess the outcomes of casirivimab-imdevimab treatment of mild to moderate COVID-19.

METHODS:

A retrospective cohort of 696 patients who received casirivimab-imdevimab between December 4, 2020 and April 9, 2021 was compared to a propensity-matched control of 696 untreated patients with mild to moderate COVID-19 at Mayo Clinic sites in Arizona, Florida, Minnesota, and Wisconsin. Primary outcome was rate of hospitalization at days 14, 21 and 28 after infusion.

FINDINGS:

The median age of the antibody-treated cohort was 63 years (interquartile range, 52-71); 45·5% were ≥65 years old; 51.4% were female. High-risk characteristics were hypertension (52.4%), body mass index ≥35 (31.0%), diabetes mellitus (24.6%), chronic lung disease (22.1%), chronic renal disease (11.4%), congestive heart failure (6.6%), and compromised immune function (6.7%). Compared to the propensity-matched untreated control, patients who received casirivimab-imdevimab had significantly lower all-cause hospitalization rates at day 14 (1.3% vs 3.3%; Absolute Difference 2.0%; 95% confidence interval (CI) 0.5-3.7%), day 21 (1.3% vs 4.2%; Absolute Difference 2.9%; 95% CI 1.2-4.7%), and day 28 (1.6% vs 4.8%; Absolute Difference 3.2%; 95% CI 1.4-5.1%). Rates of intensive care unit admission and mortality at days 14, 21 and 28 were similarly low for antibody-treated and untreated groups.

INTERPRETATION:

Among high-risk patients with mild to moderate COVID-19, casirivimab-imdevimab treatment was associated with a significantly lower rate of hospitalization.

FUNDING:

Mayo Clinic.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Etiology study / Randomized controlled trials / Risk factors Language: English Journal: EClinicalMedicine Year: 2021 Document Type: Article Affiliation country: J.eclinm.2021.101102

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Etiology study / Randomized controlled trials / Risk factors Language: English Journal: EClinicalMedicine Year: 2021 Document Type: Article Affiliation country: J.eclinm.2021.101102